Spondyloarthritis & psoriatic arthritis
Biologic DMARD class influences progression from psoriasis to PsA: a real-world cohort study
Authors' conclusion
In this long-term real-life cohort of patients with psoriasis, treatment with non-TNFi bDMARDs-particularly IL-17 and IL-23 inhibitors-was associated with lower risk of incident PsA compared with TNFi.
Study context
- Population
- Consecutive adults with psoriasis receiving bDMARDs for ≥6 months between 2008 and 2025257 single-class exposure
- Participants
- 393 adults
- Exposure
- Non-TNFi bDMARDs vs TNFi
- Outcome
- Incidence of PsA
Methodological detailstwo university dermatology-rheumatology centres, consecutive patients
- Two university dermatology-rheumatology centres
- Consecutive patients
Main finding
As reported in the abstract
Incident PsA (single-class bDMARD exposure analysis, n = 257)
PsA occurred during follow-up (all patients)
86
22%
All non-TNFi bDMARDs vs TNFi, adjusted OR range
0.16-0.25
All non-TNFi bDMARDs vs TNFi, adjusted HR range
0.17-0.30
Observational data: associations, not effects.
Further findings
Incident PsA, grouped by bDMARD class used for longest duration
- Similar findings to single-class analysis
Incident PsA, by first bDMARD received (n = 137)
- PsA prevalence and adjusted hazards did not differ between bDMARD classes
Original publication
Biologic DMARD class influences progression from psoriasis to PsA: a real-world cohort study. Rheumatology (Oxford). Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →